Compass Therapeutics Provides Corporate Update

Core Insights - Compass Therapeutics is advancing multiple first-in-class bispecific antibodies and expects to achieve major data-driven milestones in 2026 [2] - The company has strengthened its management team with the addition of Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer [2] Pipeline Highlights - Key survival analyses for tovecimig in late Q1 2026 could transform treatment for patients with biliary tract cancer [3] - The ongoing Phase 2/3 COMPANION-002 study of tovecimig is on track for late Q1 2026, focusing on progression-free survival (PFS) and overall survival (OS) [5] - CTX-8371 has shown robust responses in patients with solid and hematologic malignancies, with cohort expansions now open for enrollment in triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) [5][11] - Initial data from the Phase 1 study of CTX-10726 is expected in H2 2026, with the study initiation anticipated in Q1 2026 [5][11] Financial Position - As of December 31, 2025, Compass Therapeutics reported an estimated $209 million in cash and marketable securities, providing a cash runway into 2028 [12]